| AL | Light-chain amyloidosis |
| AML | Acute myeloid leukemia |
| ANG-1 | Angiopoietin-1 |
| ANG-2 | Angiopoietin-2 |
| aPTT | Activated partial thromboplastin |
| ASTCT | American Society for Transplantation and Cellular Therapy |
| AUC | Area under the curve |
| B-ALL | B-cell acute lymphoblastic leukemia |
| BCMA | B-cell maturation antigen |
| BTK | Bruton’s tyrosine kinase |
| CAR-T | Chimeric antigen receptor-T |
| CLL1 | C-type lectin-like molecule 1 |
| CRP | C-reactive protein |
| CRS | Cytokine release syndrome |
| DAMPs | Danger associated molecular patterns |
| EASIX | Endothelial Activation and Stress Index |
| EASIX-F | Endothelial Activation and Stress Index score combined with ferritin values |
| ECs | Endothelial cells |
| EEG | Electroencephalogram |
| FDA | Food and Drug Administration |
| FiO2 | Fraction of inspired oxygen |
| FRIDA | Frontal rhythmic intermittent delta activity |
| FVIII | Factor VIII |
| GDF-15 | Growth/differentiation factor 15 |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| HCT | Hematopoietic cell transplantation |
| HLH | Hemolytic lymphohistiocytosis |
| HMW | High molecular weight |
| ICAHT | Immune effector cell-associated hematotoxicity |
| ICAM-1 | Intercellular adhesion molecule 1 |
| ICANS | Immune effector cell-associated syndromes |
| ICE | Immune effector cell-associated encephalopathy |
| IL-1 | Interleukin 1 |
| IL-6 | Interleukin 6 |
| IL-6-mEASIX | IL-6 modified Endothelial Activation and Stress Index |
| INF-γ | Interferon-γ |
| JAK/STAT | Janus kinase/signal transducers and activators of transcription |
| LD | Lymphodepleting chemotherapy |
| LDH | Lactate dehydrogenase |
| LMW | Low molecular weight |
| MAPK/NFκB | Mitogen-activated protein kinase/nuclear factor kappa-light-chain enhancer of activated B cells |
| MAS | Macrophage activation syndrome |
| mEASIX | Modified Endothelial Activation and Stress Index |
| MM | Multiple myeloma |
| MRI | Magnetic resonance imaging |
| NETs | Neutrophil extracellular traps |
| NHL | Non-Hodgkin lymphoma |
| OS | Overall survival |
| PLTs | Platelets |
| P-mEASIX | Phosphorus-modified Endothelial Activation and Stress Index |
| PT | Prothrombin time |
| R/R | Relapsed/refractory |
| RES | Reticuloendothelial system |
| ROC | Receiver operating characteristics |
| sC5b-9 | Soluble C5b-9 |
| sEASIX | Simplified Endothelial Activation and Stress Index |
| sICAM-1 | Soluble intracellular cell adhesion molecule-1 |
| suPAR | Soluble urokinase-type plasminogen activator receptor |
| sVCAM | Soluble vascular cell adhesion molecule |
| TA-TMA | Transplant-associated thrombotic microangiopathy |
| TIE-2 | Angiopoietin-1 receptor |
| TLS | Tumor lysis syndrome |
| TNF-a | Tumor necrosis factor-a |
| VCAM-1 | Vascular cell adhesion molecule 1 |
| VEGF | Vascular endothelial growth factor |
| VWF | Von Willebrand factor |